Eculizumab, stock solution；依库丽单抗; 依库珠单抗；219685-50-4

Eculizumab (Anti-Complement C5) is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research.

Appearance： Colorless to light yellow liquid

Purity：95+%